26 march
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) has scheduled two meetings with the FDA to review the progress of developing STENDRA as the first PDE-5 inhibitor approved for over-the-counter use. The FDA has requested a listen-only meeting to review the app for improved productivity ahead of a Type C meeting on March 26, 2024, to discuss the development of the digital app and protocols for upcoming studies. Petros believes these meetings highlight the significant progress made in achieving OTC status for STENDRA and demonstrate the FDA's interest in the nonprescription development program.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
JESSE JAMES8832 : where did you get this news?
JESSE JAMES8832 : nvm i found it thanks for heads up